| Kelly Sauer Collins, MD | |
|
1406 6th Ave N, Saint Cloud, MN 56303-1900 | |
| (320) 229-4944 | |
| Not Available |
| Full Name | Kelly Sauer Collins |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 22 Years |
| Location | 1406 6th Ave N, Saint Cloud, Minnesota |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801999453 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 102626 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Cloud Hospital | Saint cloud, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Cloud Hospital | 4880594779 | 188 |
News Archive
A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.
Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.
"The growing burden of cancer in developing countries could be reduced without expensive drugs and equipment, scientists said on Monday, but it requires a global effort similar to the fight against HIV/AIDS," Reuters reports in an article that examines a study published in the Lancet by a group of American scientists who have created the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.
› Verified 8 days ago
| Entity Name | St Cloud Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043269798 PECOS PAC ID: 4880594779 Enrollment ID: O20110221000134 |
News Archive
A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.
Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.
"The growing burden of cancer in developing countries could be reduced without expensive drugs and equipment, scientists said on Monday, but it requires a global effort similar to the fight against HIV/AIDS," Reuters reports in an article that examines a study published in the Lancet by a group of American scientists who have created the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.
› Verified 8 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1275872772 PECOS PAC ID: 3870739410 Enrollment ID: O20130426000215 |
News Archive
A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.
Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.
"The growing burden of cancer in developing countries could be reduced without expensive drugs and equipment, scientists said on Monday, but it requires a global effort similar to the fight against HIV/AIDS," Reuters reports in an article that examines a study published in the Lancet by a group of American scientists who have created the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.
› Verified 8 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558600874 PECOS PAC ID: 3870739410 Enrollment ID: O20130515000683 |
News Archive
A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.
Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.
"The growing burden of cancer in developing countries could be reduced without expensive drugs and equipment, scientists said on Monday, but it requires a global effort similar to the fight against HIV/AIDS," Reuters reports in an article that examines a study published in the Lancet by a group of American scientists who have created the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Sauer Collins, MD 1406 6th Ave N, St Cloud, MN 56303-1900 Ph: (320) 229-4944 | Kelly Sauer Collins, MD 1406 6th Ave N, Saint Cloud, MN 56303-1900 Ph: (320) 229-4944 |
News Archive
A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.
Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.
"The growing burden of cancer in developing countries could be reduced without expensive drugs and equipment, scientists said on Monday, but it requires a global effort similar to the fight against HIV/AIDS," Reuters reports in an article that examines a study published in the Lancet by a group of American scientists who have created the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.
› Verified 8 days ago
Sakshi Kaul, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1200 6th Ave N, Saint Cloud, MN 56303 Phone: 202-865-6100 | |
Dr. Christina Ann Jenner, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 4801 Veterans Dr, Saint Cloud, MN 56303 Phone: 320-252-1670 | |
Elizabeth Baillargeon, MD Physical Medicine & Rehabilitation Medicare: May Accept Medicare Assignments Practice Location: 1900 Centracare Cir, Saint Cloud, MN 56303 Phone: 320-229-4922 | |
Madison Jo Clayton, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2835 W Saint Germain St, Saint Cloud, MN 56301 Phone: 320-259-4151 |